Simulations Plus (NASDAQ:SLP) Releases FY 2026 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 1.030-1.100 for the period, compared to the consensus estimate of 1.000. The company issued revenue guidance of $79.0 million-$82.0 million, compared to the consensus revenue estimate of $80.5 million.

Simulations Plus Trading Down 4.9%

Simulations Plus stock opened at $17.71 on Friday. The company has a 50-day moving average price of $19.04 and a 200 day moving average price of $16.48. Simulations Plus has a 12-month low of $12.39 and a 12-month high of $37.67. The stock has a market cap of $356.86 million, a P/E ratio of -5.53 and a beta of 1.09.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.05). The firm had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same period last year, the company earned $0.17 EPS. As a group, analysts forecast that Simulations Plus will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

SLP has been the subject of a number of recent analyst reports. Citigroup reissued a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. BTIG Research cut shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. KeyCorp restated a “sector weight” rating on shares of Simulations Plus in a report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Simulations Plus in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Simulations Plus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $25.00.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SLP. Raymond James Financial Inc. acquired a new stake in shares of Simulations Plus during the 2nd quarter worth about $25,000. Quarry LP purchased a new position in Simulations Plus in the third quarter valued at approximately $28,000. US Bancorp DE raised its holdings in Simulations Plus by 32.5% during the third quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock worth $93,000 after purchasing an additional 1,513 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Simulations Plus by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after buying an additional 390 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new position in shares of Simulations Plus in the 3rd quarter valued at $155,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.